Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | ERN1 | O75460 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29084623 | 0.86 | ALDH1A1 (0.46) | ALDH1A1ERN1LMNATLR2TLR1 | |
| SCHEMBL1813429 | 0.84 | ALDH1A1 (0.45) | ALDH1A1ERN1LMNATLR2TLR1 | |
| SCHEMBL19317495 | 0.84 | ERN1 (0.48) | ALDH1A1ERN1LMNATLR2TLR1 | |
| SCHEMBL19025079 | 0.84 | ERN1 (0.51) | ALDH1A1ERN1LMNATLR2TLR1 | |
| SCHEMBL172818 | 0.84 | ERN1 (0.66) | ALDH1A1ERN1LMNATLR2TLR1 | |
| SCHEMBL29442477 | 0.84 | ERN1 (0.66) | ALDH1A1ERN1LMNATLR2TLR1 | |
| SCHEMBL6905536 | 0.79 | TSHR (0.42) | ALDH1A1ERN1LMNATLR2TLR1 | |
| SCHEMBL1527154 | 0.79 | ERN1 (0.69) | ALDH1A1ERN1TLR2TLR1TLR6 | |
| Ethylenediamine SCHEMBL10537022 | 0.77 | ERN1 (0.57) | ALDH1A1ERN1TLR2TLR1TLR6 | |
| SCHEMBL295293 | 0.76 | ALDH1A1 (0.51) | ALDH1A1ERN1LMNAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114804659-B | Antioxidant high-strength glass fiber and preparation method thereof | 盛夏新能源汽车材料(昆山)有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119638218-A | Antioxidant high-strength glass fiber | 周炳胜 | 2025-03-18 | — | — | CN | claimed |
| CN-114804659-A | Antioxidant high-strength glass fiber and preparation method thereof | 周炳胜 | 2022-07-29 | — | — | CN | claimed |
| CN-114804659-B | Antioxidant high-strength glass fiber and preparation method thereof | 盛夏新能源汽车材料(昆山)有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-114804659-B | Antioxidant high-strength glass fiber and preparation method thereof | 盛夏新能源汽车材料(昆山)有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119638218-A | Antioxidant high-strength glass fiber | 周炳胜 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638218-A | Antioxidant high-strength glass fiber | 周炳胜 | 2025-03-18 | — | — | CN | disclosed |
| CN-114804659-A | Antioxidant high-strength glass fiber and preparation method thereof | 周炳胜 | 2022-07-29 | — | — | CN | disclosed |
| CN-114804659-A | Antioxidant high-strength glass fiber and preparation method thereof | 周炳胜 | 2022-07-29 | — | — | CN | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1601348-A4 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE INC (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1601348-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | ALDH1A1 553/4885ERN1 3895/4885LMNA 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.